Acta Scientific Clinical Case Reports

Review ArticleVolume 3 Issue 5

Management of Chronic Anal Fissure by Botulinum Toxin Injection: An Article Review

YN Irkal and Amruth H Basava*

Shreeya Multispeciality Hospital, Dharwad, Karnataka, India

*Corresponding Author: Amruth H Basava, Shreeya Multispeciality Hospital, Dharwad, Karnataka, India.

Received: April 07, 2022; Published: April 21, 2022

Abstract

Chronic anal fissure (CAF) is a painful anal condition with an underlying pathophysiology of increased resting internal sphincter tone causing local ischaemia from prolonged compression of anodermal arteries. Botulinum Toxin type-A (BTX-A) is a minimally invasive management of CAF which causes reversible ‘chemical sphincterotomy’ of internal anal sphincter and reduces the anal tone. This article review analyses 6 studies which have evaluated BTX-A injection in CAF management through various aspects including its efficacy (short-term and long-term), pain relief, safety, role of patient factors, improvement in quality of life, and dose-dependent efficiency. A former meta-analytic study (6) concludes that the efficiency and postoperative incontinence rate is not dose-dependent. Moreover, the healing rates remain similar regardless of the site and number of injections per session. The results of studies are comparable with a success rate of 64.8% to 86.85% and the main side-effect of transient faecal incontinence observed in 8.6% to 13.2%. Although BTX-A injection is a safe and effective minimally invasive treatment in CAF with failed conservative management, there is a significant long-term treatment failure.

Keywords: Chronic Anal Fissure; BTX-A; Pathophysiology

Bibliography

  1. Hassan K., et al. “Evaluation of botulinum toxin therapy for chronic anal fissure”. Journal of Medicine in Scientific Research 2 (2018): 114.
  2. Amorim H., et al. “Botulinum toxin improves pain in chronic anal fissure”. Porto Biomedical Journal6 (2017): 273-276.
  3. Barbeiro S., et al. “Long-term outcomes of Botulinum toxin in the treatment of chronic anal fissure: 5 years of follow-up”. United European Gastroenterology Journal2 (2016): 293-297.
  4. Hemmati H., et al. “Therapeutic properties of botulinum toxin on chronic anal fissure treatment and the patient factors role”. Journal of Family Medicine and Primary Care3 (2020): 1562.
  5. Bagul A and Carter P. “Quality of Life in Patients Receiving Botulinum A Toxin Treatment for Symptomatic Anal Fissure”. World Journal of Surgery and Surgical Research 2 (2019): 1130th ser.
  6. Bobkiewicz A., et al. “Botulinum Toxin Injection for Treatment of Chronic Anal Fissure: Is There Any Dose-Dependent Efficiency? A Meta Analysis”. World Journal of Surgery 40 (2016): 3064-3072.

Citation: YN Irkal and Amruth H Basava. “Management of Chronic Anal Fissure by Botulinum Toxin Injection: An Article Review". Acta Scientific Clinical Case Reports 3.5 (2022): 76-79.

Copyright: © 2022 YN Irkal and Amruth H Basava. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 20, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US